Items tagged with Drug-resistant TB

RESIST-TB webinar: Hear about endTB results (post)

RESIST-TB will host a webinar on 30 May 2024 on endTB trial results. Dr. Mikanda Kunda, a Lesotho Principal Investigator for endTB trials and STEM-TB observational study, will be presenting.

Latest TB research publications (post)

New partnership to improve access to new antibiotics in low- and middle-income countries to boost efforts to combat TB and AMR (post)

The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF) announced a partnership agreement to improve global access to antibiotics. GDF will incorporate GARDP’s portfolio of antibiotics to improve appropriate and affordable antibiotic access for the benefit of patients and health systems, particularly in low- and middle-income countries.

RESIST-TB June 2024 newsletter (post)

RESIST-TB released its June 2024 newsletter with the latest updates and research publications on drug-resistant TB.

RESIST-TB July 2024 newsletter (post)

RESIST-TB released its July 2024 newsletter with the latest updates and research publications on drug-resistant TB.

NHS England: Clinical commissioning policy statement for the treatment of drug-resistant TB (post)

The National Health Service (NHS) in England released Clinical commissioning policy statement, and accompanying documents, for the treatment for defined patients with rifampicin-resistant TB, multidrug-resistant TB, pre-extensively drug-resistant TB and extensively drug-resistant TB including bedaquiline and delamanid (all ages).

FDA grants traditional approval to TB treatment Sirturo (post)

The Food and Drug Administration (FDA) has granted traditional approval to Sirturo^® (bedaquiline) for use as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.

New biomarker identified for predicting adverse events of TB therapy (post)

Borstel researchers are the first to develop a biomarker to predict the occurrence of neuropathic adverse events during therapy for multidrug-resistant tuberculosis. The results have now been published in the journal Pathogens & Immunity.

Johnson & Johnson agrees to lower price of TB drug bedaquiline, allow production in South Africa (post)

South Africa's anti-trust regulator announced on July 5 that drugmaker Johnson & Johnson (J&J) and its subsidiary, Janssen Pharmaceutical, have agreed to withdraw a secondary patent on the tuberculosis (TB) drug bedaquiline.

Johnson & Johnson's patent for paediatric TB drug rejected in India, move hailed as 'significant victory' for children (post)

New Delhi: In a big victory for TB activism and children suffering from TB in India, the country’s patent office rejected Johnson & Johnson’s (J&J) patent application for the paediatric formulation of Bedaquiline on Friday, July 5.